News | March 19, 2026
Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
SPARK has extended its influence to an additional 9.47 million students worldwide
SPARK has extended its influence to an additional 9.47 million students worldwide
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated
